Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM/Nasdaq: PHAR) announces that at its Annual General Meeting of Shareholders (AGM) held today, the proposal for a specific authorization for the issuance of shares (or rights to acquire shares) to finance mergers, acquisitions, or strategic alliances, was not put up for a vote. All other proposals were approved.

Pharming Group N.V. presents its preliminary, unaudited financial report for the first quarter ended March 31, 2023.

Pharming Group N.V. confirms it will announce first quarter 2023 financial results for the month ended March 31, 2023 on Thursday, May 11, 2023.

Pharming Group N.V. announces the filing of its Annual Report for the year ended December 31, 2022 (the “Period”).

Pharming Group N.V. presents its preliminary (unaudited) financial report for the full year ended December 31, 2022. Download the press release below.

Pharming Group N.V. is aware that the Federal Deposit Insurance Corporation (“FDIC”) has been appointed receiver of Silicon Valley Bank (“SVB US”) and that the Bank of England, barring any intervening events, intends to put Silicon Valley Bank UK Limited (“SVB UK”) into insolvency.

Pharming Group N.V. confirms it will announce its unaudited Full Year 2022 financial results for the year ended December 31, 2022, on Thursday, March 16, 2023.

Pharming Group N.V. presents its preliminary, unaudited financial report for the first nine months ended September 30, 2022.